Nicotine-Related Impurities in E-Cigarette Cartridges and Refill Formulations

Jason W. Flora, Celeste Wilkinson, Kathleen M. Sink, Diana L. McKinney, John H. Miller

Altria Client Services LLC, 601 East Jackson Street, Richmond, VA 23219




Background

- The nicotine used in e-cigarette formulations is extracted from tobacco, and the purity of the nicotine can vary depending upon manufacturer and grade (e.g., US Pharmacopeia grade)
- The US and European Pharmacopeia make recommendations for the purity of nicotine intended for pharmaceutical products
- Recommendations are also made in the ICH Guidelines "Impurities in New Drug Products Q3B(R2)"*

peer-reviewed by CORESTA Document not

*Q3B(R2): International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. Impurities in New Drug Products. International Conference on Harmonisation. 2006.






Background

- No official purity recommendation for the nicotine used in e-cigarettes has been made
- Only a few publications have evaluated the nicotine-related impurities in e-cigarette formulations and none have evaluated these e-liquids during long-term storage
- Etter, J. F., Zather, E., Svensson, S., Analysis of refill liquids for electronic cigarettes. Addiction 2013, 108 (9), 1671-1679.
- Trehy, M. L., Ye, W., Hadwiger, M. E., Moore, T. W. *et al.* Analysis of Electronic Cigarette Cartridges, Refill Solutions, and Smoke for Nicotine and Nicotine Related Impurities. *Journal of Liquid Chromatography & Related Technologies* **2011**, 34 (14), 1442-1459.
- Westenberger, B., Evaluation of e-cigarettes. Washington, DC: US Food and Drug Administration, 2009.
- Westenberger, B., Evaluation of Johnson Creek Liquids for E-cigarette Fills. Washington, DC: US Food and Drug Administration, 2009.
- Flora J.W., Meruva N., Huang C.B, Wilkinson C.T., Ballentine R., Smith D.C., Werley M.S., McKinney W.J, Characterization of potential impurities and degradation products in electronic cigarette formulations and aerosols, Regul. Toxicol. Pharmacol. **2016**, 74, 1-11.



Background

- FDA recommends a list of constituents to be measured in e-vapor products and e-liquids
- "FDA also recommends that you include a complete list of uniquely identified constituents, including those listed below, as appropriate for your product, and other toxic chemicals contained within the product or delivered by the product, such as a reaction product from leaching or **aging** and aerosol generated through the heating of the product."*








*Premarket Tobacco Product Applications for Electronic Nicotine Delivery Systems Guidance for Industry – Draft – CTP-FDA - 2016

Objectives

- To develop a sensitive, selective, and robust analytical method (LC-MS) for the quantitation of nicotine-related impurities and degradation products in e-vapor products
- To evaluate these impurities in a variety of commercial e-cigarette cartridges and refill solutions (e-liquids).
- To quantify changes in these impurities during long-term storage of commercial e-cigarettes
- To apply this method to estimate the transfer efficiency of the nicotinerelated impurities to the aerosol





Altria Altria Client Services

Altria Client Services | Principal Scientist | 2016 6

Altria Client Services | Principal Scientist | 2016 7

Use.

Analytical Methodologies

Analyte	Analytical Platform
Nicotine	GC-FID
Nicotine-Related Impurities	LC-MS/MS
	Gas Chromatograph with Flame Ionization Detector iquid Chromatography with Mass Spectrometry

- Formulations from disposable e-cigarette cartridges were removed by centrifugation at 4800 rpm for 30 seconds
- Sealed tank models were disassembled and formulation was removed
- Refill e-liquids were pipetted directly for analysis

Itria Client Services

 Method validations were conducted consistent with ICH guidelines "Validation of Analytical Procedures: Test and Methodology Q2(R1)"*

> *Q2(R1): International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. Validation of Analytical Procedures. International Conference on Harmonisation. 2005.


CORESTA

Document not peer-reviewed by

ongress2016

Nicotine Method

- For all samples, formulations were diluted in *n*-propanol containing quinoline as the internal standard
- All data were collected on either an Agilent 7890 or 6890 GC with FID detection
- The analytical column used was a DB-ALC1 fused silica capillary column, 30 m × 0.320 mm ID, 1.8 m film thickness (Agilent Technologies), and the carrier gas was helium





Nicotine-Related Impurities Method

- For all samples, formulation was diluted in 70/30 methanol/water containing deuterium labeled internal standards
- Chromatography Waters ACQUITY UPLC with X-Bridge C18 (2.5um) 2.1 x 50 mm column
- Mobile phase A is 10 mM ammonium acetate (pH 10) and mobile phase B is optima grade methanol (gradient run)
- MS detection using Multiple Reaction Monitoring (MRM)



Analyte	Internal Standard			
Myosmine	Myosmine-d4			
Nornicotine	Nornicotine-d4			
β-nicotyrine	Myosmine-d4			
Anatabine	Myosmine-d4			
Anabasine	Anabasine-d4			
Cotinine	Cotinine-d3			
Nicotine-N-oxide	Cotinine-d3			

Commercial Refill E-Liquids Tested (Jan 2016)

product code	type	percent nicotine by weight	production date	"expiration", "sell by", or "do not use after" Date	Package	
1	refill e-liquid	1.2	-	-	glass bottle with plastic overwrap	
2	refill e-liquid	1.2	-	-	glass bottle with plastic overwrap	
3	refill e-liquid	1.2	-	5/19/2016	plastic bottle with plastic overwrap	
4	refill e-liquid	1.2	-	5/15/2016	plastic bottle with plastic overwrap	
5	refill e-liquid	1.2	-	6/23/2016	glass bottle	
6	refill e-liquid	1.2	-	10/8/2016	glass bottle	
7	refill e-liquid	1.2	-	-	glass bottle with plastic overwrap	
8	refill e-liquid	1.2	-	-	glass bottle with plastic overwrap	
9	refill e-liquid	1.6	8/1/2014	8/1/2016	plastic bottle with plastic overwrap	
10	refill e-liquid	1.6	-	5/23/2015	plastic bottle with plastic overwrap	

Limited production and shelf life data provided from manufacturers

Variety of packaging configurations and product ages Altria Altria Client Services 201

Commercial E-Cigarettes Tested (Jan 2016)

product code	type	percent nicotine by weight	production date	"expiration", "sell by", or "do not use after" Date	Package	
11	disposable prefilled tank	1.8	12/3/2014	12/3/2015	blister pack with rubber mouthpiece cover	
12	disposable prefilled tank	5.0	-	-	blister pack with plastic backing	
13	disposable prefilled tank	2.4	-	12/18/2016	plastic box with rubber or plastic endcaps	
14	disposable device	1.8	-	2/10/2013	plastic box with rubber or plastic endcaps	
15	disposable device	1.8	-	2/10/2013	plastic box with rubber or plastic endcaps	
16	disposable device	4.5	-	-	Plastic box with plastic overwrap	
17	disposable cartridge	4.8	-	-	blister pack with foil backing	
18	disposable cartridge	2.4	-	8/1/2016	blister pack with foil backing	
19	disposable cartridge	3.5	-	5/9/2016	blister pack with foil backing	
20	disposable cartridge	1.6	-	-	plastic overwrap, blister with foil backing	


Limited production and shelf life data provided from manufacturers

Variety of packaging configurations and product ages

Altria Client Services

201

Nicotine Level: Labelled vs. Measured



*18 and 19 are MarkTen® e-cigarettes manufactured by NuMark LLC




201

Nicotine Level: Labelled vs. Measured

- 6 products contained nicotine between 90 and 100% of label claim
 - 4 had shelf life information
 - 1 was expired
- In 1 products contained nicotine between 70 and 90% of the label claim
 - 6 had shelf life information
 - 1 was expired
- 3 products contained nicotine less than 50% of the nicotine label claim
 - 2 had shelf life information
 - 2 were expired



Nicotine-Related Impurities



2016 ST38_FI

Nicotine-Related Impurities

- Myosmine, anabasine, β-nicotyrine, cotinine, and nornicotine, all had values below 0.2% of the labelled nicotine content where many were well below 0.1%
- Products 10, 13, and 20 had relatively high average anatabine levels at 0.57, 0.47, and 0.41%
- 6 of the 20 products contained nicotine-N-oxide levels greater than 0.5% of the labelled nicotine content
 - 3 were expired
 - 2 were within labelled shelf life
 - 1 had no shelf life information



Nicotine-Related Impurities During Shelf-life

- To quantify changes in these impurities during long-term storage of commercial e-cigarettes
- MarkTen® XL e-cigarettes manufactured by NuMark LLC were evaluated during long-term storage (Classic and Menthol)

Storage Description	Storage Conditions			
Long-term (Q1A(R2))*	25°C ± 2°C / 60% RH ± 5%			


Tested at 1, 2, 4 and 6 months




* ICH Guidance for Industry Q1A(R2) Stability Testing of New Drug Substances and Products

Nicotine-Related Impurities During Shelf-life

- All specified impurities are <0.2% of the total nicotine concentration after 6 months at long-term conditions
- No measurable increase was observed for anabasine, β-nicotyrine, and anatabine





Estimate the % transfer efficiency to the aerosol (n=6)

Itria Client Services

Transfer % in aerosol	Myosmine	Nornicotine	Cotinine	Anabasine	Nicotine-N- Oxide	Anatabine	B-nicotyrine
MarkTen® Classic	97	95	103	80	5.4	89	141
MarkTen® Menthol	97	110	103	91	4.9	96	164

Non-validated method

GC-MS analysis of nicotine-N-oxides showed primary thermal decomposition pathways were to nicotine and β -nicotyrine

Conclusions

- Shelf-life information on e-cigarettes and refill e-liquids should be established through rigorous stability testing measuring a variety of constituents appropriate for the products
- This selective and sensitive method is suitable to provide quantitative data for risk assessment analysis and for use in e-vapor product and refill solution stability studies as one of the stability indicating measures
- Nicotine-N-oxide, nornicotine, mysomine, and cotinine have been observed to increase with respect to time during stability studies*
- Transfer efficiency of nicotine-N-oxide is low (<10%) due to thermal degradation during the aerosol formation process



* ICH Guidance for Industry Q1A(R2) Stability Testing of New Drug Substances and Products

Acknowledgements: Celeste Wilkinson, Kathleen M. Sink, Diana L. McKinney, John H. Miller, Chris McFarlane, George Karles

This presentation may be accessed @ www.altria.com/ALCS-Science